ANTA Sports Products Limited Goes Ex Dividend Tomorrow

Seeking AlphaSep 9 09:52 ET

Continued heat! Technology stocks have sparked a wave of stock buybacks in the Hong Kong stock market. Which companies are worth paying attention to?

What impact will the diversified trend of share buybacks in the Hong Kong stock market have?

cls.cnSep 8 21:10 ET

[Brokerage Focus] Haitong Securities maintains a “outperform” rating on Anta Sports (02020), bullish on the growth potential of multiple brands.

Haitong Securities released a research report stating that Anta Sports (02020) 24H1 revenue increased by 13.8% year-on-year to 33.74 billion yuan, with a gross margin increase of 0.8 percentage points to 64.1%, and a 62.6% increase in net income attributable to the mother to 7.72 billion yuan, with a net margin increase of 6.9 percentage points to 22.9%. The bank determines that the main reasons for the revenue growth are: ① a 25.1% increase in e-commerce revenue, ② increased functional products and footwear products from Anta and FILA, ③ improvement in store efficiency and discount for DTC model (Anta brand) and direct retail (FILA and other brands), ④ the continued improvement of the high-end outdoor sports track.

金吾財訊Sep 6 04:56 ET

ANTA Sports spent approximately 99.9586 million Hong Kong dollars to repurchase 1.3326 million shares on September 5th.

ANTA Sports (02020) announced that on September 5, 2024, it will repurchase approximately 1.3326 million shares of stock at a cost of approximately HKD 99.9586 million.

新浪港股Sep 5 19:05 ET

Hong Kong Stock Exchange Announcement | Bank of Zhengzhou intends to sell assets held by Zhongyuan Assets for 10 billion yuan.

Zhiyun Health (09955) has obtained the exclusive rights in China for the importation, distribution, sales, and promotion of Livemin and Shibao Litong tablets in hospitals and pharmacies for five years.

Zhitong FinanceSep 4 11:07 ET

Gelonghui Announcement Selection (Hong Kong Stocks) | Zhiyun Health (09955.HK) has obtained the exclusive rights to import, distribute, sell, and promote Levofloxacin Tablets and Ciprofloxacin Tablets in hospitals and pharmacies in China for five years.

[Today Focus] Zhiiyun Health (09955.HK) announced that the company has entered into a non-legally binding strategic cooperation agreement with Xiapu Natural Pharmaceutical Company ("Xiapu Pharmaceutical") and a subsidiary of Medici Pharmaceuticals Limited (Medici) on September 4, 2024, and obtained the exclusive rights to import, distribute, sell, and promote Levomin tablets and Shibo Litong tablets in Chinese hospitals and pharmacies for five years. Medici is a leading German family pharmaceutical company, and is affiliated with

Gelonghui FinanceSep 4 10:54 ET